JP2020510075A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510075A5 JP2020510075A5 JP2019550800A JP2019550800A JP2020510075A5 JP 2020510075 A5 JP2020510075 A5 JP 2020510075A5 JP 2019550800 A JP2019550800 A JP 2019550800A JP 2019550800 A JP2019550800 A JP 2019550800A JP 2020510075 A5 JP2020510075 A5 JP 2020510075A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutically acceptable
- acceptable salt
- therapeutic agent
- erα
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002401 inhibitory effect Effects 0.000 claims 26
- 239000003112 inhibitor Substances 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 23
- 239000011780 sodium chloride Substances 0.000 claims 23
- 239000003814 drug Substances 0.000 claims 17
- 102100019398 CDK4 Human genes 0.000 claims 11
- 101700008359 CDK4 Proteins 0.000 claims 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- AHJRHEGDXFFMBM-UHFFFAOYSA-N Palbociclib Chemical group N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 5
- 229960004390 Palbociclib Drugs 0.000 claims 5
- -1 Pyridine-2-yl Chemical group 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- NQQRXZOPZBKCNF-UHFFFAOYSA-N but-2-enamide Chemical compound CC=CC(N)=O NQQRXZOPZBKCNF-UHFFFAOYSA-N 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- PYWAWXBVLNWBDP-UHFFFAOYSA-N 3-fluoro-2H-indazole Chemical compound C1=CC=CC2=C(F)NN=C21 PYWAWXBVLNWBDP-UHFFFAOYSA-N 0.000 claims 2
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- UZWDCWONPYILKI-UHFFFAOYSA-N N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- NQQRXZOPZBKCNF-NSCUHMNNSA-N (E)-but-2-enamide Chemical compound C\C=C\C(N)=O NQQRXZOPZBKCNF-NSCUHMNNSA-N 0.000 claims 1
- 229950001573 Abemaciclib Drugs 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 229950003687 Ribociclib Drugs 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762472345P | 2017-03-16 | 2017-03-16 | |
US62/472,345 | 2017-03-16 | ||
PCT/US2018/022961 WO2018170447A1 (en) | 2017-03-16 | 2018-03-16 | Combination therapies for the treatment of breast cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020510075A JP2020510075A (ja) | 2020-04-02 |
JP2020510075A5 true JP2020510075A5 (US20080131398A1-20080605-C00009.png) | 2021-04-30 |
JP7219224B2 JP7219224B2 (ja) | 2023-02-07 |
Family
ID=61874039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019550800A Active JP7219224B2 (ja) | 2017-03-16 | 2018-03-16 | 乳癌の治療のための組合せ療法 |
Country Status (14)
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102425785B1 (ko) * | 2016-11-28 | 2022-07-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 인다졸 유도체의 염 및 이의 결정 |
AU2019205821B2 (en) | 2018-01-08 | 2024-07-18 | G1 Therapeutics, Inc. | G1T38 superior dosage regimes |
US20230404987A1 (en) * | 2020-11-06 | 2023-12-21 | Eisai R&D Management Co., Ltd. | Method of treating breast cancer |
CN113018357A (zh) * | 2021-02-08 | 2021-06-25 | 湖南农业大学 | 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途 |
WO2024115680A1 (en) | 2022-12-01 | 2024-06-06 | Krka, D.D., Novo Mesto | Ribociclib salts and formulations thereof |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
DE19959546A1 (de) | 1999-12-09 | 2001-06-21 | Rhone Poulenc Rorer Gmbh | Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen |
JP2003520797A (ja) | 2000-01-18 | 2003-07-08 | アベンテイス・フアーマシユーチカルズ・インコーポレーテツド | (−)−シス−2−(2−クロロフェニル)−5,7−ジヒドロキシ−8[4R−(3S−ヒドロキシ−1−メチル)ピペリジニル]−4H−1−ベンゾピラン−4−オンの偽多形体(pseudopolymorph) |
IL150643A0 (en) | 2000-01-18 | 2003-02-12 | Aventis Pharma Inc | Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 [4r-(3s-hydroxy-1-methyl) piperidinyl]-4h-1-benzopyran-4-one |
US20050004007A1 (en) | 2000-09-12 | 2005-01-06 | Steven Grant | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
GEP20063909B (en) | 2002-01-22 | 2006-08-25 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES |
PL2256106T3 (pl) | 2003-07-22 | 2015-08-31 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
US20090036435A1 (en) | 2005-01-21 | 2009-02-05 | Astex Therapeutics Limited | Pharmaceutical Compounds |
MX2007008809A (es) | 2005-01-21 | 2007-09-07 | Astex Therapeutics Ltd | Combinaciones de inhibidores de pirazol cinasa y otros agentes antitumor. |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
CA2594474C (en) | 2005-01-21 | 2016-03-29 | Astex Therapeutics Limited | Pharmaceutical compounds |
JP2008255008A (ja) | 2005-07-19 | 2008-10-23 | Tokyo Medical & Dental Univ | 滑膜細胞増殖抑制剤 |
US7776832B2 (en) * | 2006-04-21 | 2010-08-17 | Gem Pharmaceuticals, Llc | Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines |
JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
WO2008001101A2 (en) | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations |
US20100021420A1 (en) | 2006-07-14 | 2010-01-28 | Astex Therapeutics Limited | Combinations of pyrazole derivatives for the inhibition of cdks and gsk's |
EP2049106A2 (en) | 2006-07-14 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
JP2009544602A (ja) | 2006-07-21 | 2009-12-17 | アステックス・セラピューティクス・リミテッド | サイクリン依存性キナーゼ阻害剤の医学的使用 |
US7902147B2 (en) | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
GEP20135785B (en) | 2008-08-22 | 2013-03-11 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
EP2558092B1 (en) | 2010-04-13 | 2018-06-27 | Novartis AG | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
GB2483736B (en) * | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
SI2632467T1 (sl) | 2010-10-25 | 2016-10-28 | G1 Therapeutics, Inc. | Inhibitorji CDK |
US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
WO2012129344A1 (en) | 2011-03-23 | 2012-09-27 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
MX2015006809A (es) | 2012-11-28 | 2015-08-06 | Novartis Ag | Terapia de combinacion. |
LT2968290T (lt) | 2013-03-15 | 2019-12-10 | G1 Therapeutics Inc | Laikina normalių ląstelių apsauga chemoterapijos metu |
EP3033086B1 (en) | 2013-08-14 | 2021-09-22 | Novartis AG | Combination therapy for the treatment of cancer |
JP2017507964A (ja) | 2014-03-13 | 2017-03-23 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーターを用いた治療的組合せ |
WO2016025650A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
CN104529904B (zh) | 2015-01-09 | 2016-08-31 | 苏州明锐医药科技有限公司 | 玻玛西尼的制备方法 |
US20160220569A1 (en) | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
IL255148B2 (en) * | 2015-04-29 | 2023-04-01 | Radius Pharmaceuticals Inc | 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation |
JP6325760B1 (ja) * | 2015-05-29 | 2018-05-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 四置換アルケン化合物及びその使用 |
-
2018
- 2018-03-16 WO PCT/US2018/022961 patent/WO2018170447A1/en unknown
- 2018-03-16 AU AU2018234903A patent/AU2018234903B2/en active Active
- 2018-03-16 CN CN201880030008.9A patent/CN110636862A/zh active Pending
- 2018-03-16 MX MX2019010981A patent/MX2019010981A/es unknown
- 2018-03-16 BR BR112019019261-1A patent/BR112019019261A2/pt unknown
- 2018-03-16 SG SG11201908531W patent/SG11201908531WA/en unknown
- 2018-03-16 JP JP2019550800A patent/JP7219224B2/ja active Active
- 2018-03-16 IL IL269357A patent/IL269357B1/en unknown
- 2018-03-16 EP EP23159590.1A patent/EP4218820A3/en not_active Withdrawn
- 2018-03-16 MA MA047776A patent/MA47776A/fr unknown
- 2018-03-16 KR KR1020197029851A patent/KR102517650B1/ko active IP Right Grant
- 2018-03-16 RU RU2019132893A patent/RU2764724C2/ru active
- 2018-03-16 US US16/493,931 patent/US11083722B2/en active Active
- 2018-03-16 CA CA3056701A patent/CA3056701A1/en active Pending
- 2018-03-16 EP EP18715441.4A patent/EP3595725B1/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020510075A5 (US20080131398A1-20080605-C00009.png) | ||
JP7330312B2 (ja) | Hivを治療するためのトール様受容体の調節因子 | |
JP2020002146A (ja) | イブルチニブ併用療法 | |
RU2478387C2 (ru) | ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR | |
JP2019511526A5 (US20080131398A1-20080605-C00009.png) | ||
UA121630C2 (US20080131398A1-20080605-C00009.png) | ||
US20080207572A1 (en) | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | |
KR20160066554A (ko) | 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료 | |
JP2013541595A5 (US20080131398A1-20080605-C00009.png) | ||
JP2015143278A (ja) | 治療用組成物およびその使用 | |
RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
RU2600793C2 (ru) | Новый режим приема n-гидрокси-4-{2-[3-(n, n-диметиламинометил)бензофуран-2-илкарбониламино]этокси}бензамида | |
JP2015143277A (ja) | 治療組成物およびその使用 | |
CN103118682A (zh) | 合成tlr7激动剂的磷脂缀合物的用途 | |
KR20090013827A (ko) | Hiv 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ccr5 길항제 | |
KR20180042356A (ko) | 암 치료 방법 | |
JP2015522630A5 (US20080131398A1-20080605-C00009.png) | ||
JP2019511529A5 (US20080131398A1-20080605-C00009.png) | ||
RU2019132893A (ru) | Комбинированная терапия для лечения рака молочной железы | |
ECSP066318A (es) | Composición para la liberación de una base debil por un periodo extendido de tiempo | |
WO2009147218A1 (en) | Pharmaceutical combination | |
CN101808636A (zh) | 黑色素瘤的治疗 | |
JP2019528302A5 (US20080131398A1-20080605-C00009.png) | ||
RU2019108259A (ru) | Комбинированная терапия для лечения гепатоцеллюлярной карциномы |